A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if adding extended-release galantamine
hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well
tolerated and effective in improving cognitive impairment in patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.